Next generation antibody drug conjugates (ADCs) and immunotoxins. (2017)

• Record Type: Book
• Further Information: Note: Ulf Grawunder, Stefan Barth, editors.
• Editors: Grawunder, Ulf; Barth, Stefan
• Contents: Preface; The Complexity of ADCs and ITs; Contents; Chapter 1: Chemical Assembly of Antibody-Drug Conjugates; 1.1 Introduction; 1.2 Conjugation via Natural Amino Acid Residues; 1.2.1 Random Conjugation at Native Cysteine Residues; 1.2.2 Site-Specific Conjugation at Engineered Cysteine Residues; 1.2.3 Stabilization of Maleimide Linkage; 1.2.4 Hydrophilic Spacers; 1.2.5 Cysteine-Bridged Conjugation; 1.2.6 Site-Specific Conjugation at Engineered Selenocysteine Residues; 1.2.7 Random Conjugation at Native Lysine Residues; 1.2.7.1 Maytansinoid ADCs; 1.2.7.2 Calicheamicin ADCs. 1.3 Conjugation via Unnatural Amino Acids1.3.1 Site-Specific Conjugation at Engineered p-Acetyl-Phe Residues; 1.3.2 Site-Specific Conjugation at Engineered p-Azidomethyl-Phe Residues; 1.3.3 Site-Specific Conjugation at Engineered Formylglycine Residues; 1.4 Conclusions; References; Chapter 2: Preclinical Evaluation of ADCs Delivering Highly Potent Pyrrolobenzodiazepine (PBD) Dimers; 2.1 Background to the PBDs; 2.2 Antibody PBD Conjugates (APCs); 2.2.1 C2-Linked APCs; 2.2.2 N10-Linked APCs; 2.3 Emerging Clinical Data; 2.4 Properties and Advantages of APCs; 2.5 Conclusions; References. Chapter 3: Stable and Homogeneous Drug Conjugation by Sequential Bis-Alkylation at Disulphide Bonds Using Bis-Sulphone Reagents3.1 Introduction; 3.2 Bis-Sulphone Reagents for Disulphide Bridging Conjugation; 3.3 Reagent; 3.4 ADC Characterisation; 3.4.1 ADC Stability; 3.5 In Vitro Potency; 3.6 In Vivo Efficacy; 3.7 Antibody Fragments; 3.8 Fab Drug Conjugates; 3.9 Imaging Applications; 3.10 Conclusion; References; Chapter 4: Calicheamicin Antibody-Drug Conjugates for Liquid and Solid Tumor Indications; 4.1 Mechanism of Action of Calicheamicin as an ADC Payload. 4.2 Preclinical Activities of Inotuzumab Ozogamicin4.3 Preclinical and Clinical Experience with Gemtuzumab Ozogamicin; 4.4 Ephrin-A4 (EFNA4): A Novel Target for Calicheamicin Conjugates; 4.5 Antitumor Activity of the EFNA4-ADC Against CSCs in Triple Negative Breast Cancer (TNBC) and Ovarian Carcinomas (OVCA)PDX ... ; 4.6 Conclusions and Future Perspectives; References; Chapter 5: Enzyme-Based Strategies to Generate Site-Specifically Conjugated Antibody Drug Conjugates; 5.1 Introduction; 5.2 Enzymatic Conjugation Technologies Used for the Generation of Site-Specifically Conjugated ADCs. 5.2.1 Strategies Involving Bacterial Transglutaminase (BTG) Enzyme5.2.2 Use of Sortase Enzymes for Generating Homogeneous ADCs; 5.2.3 Formyl-glycine Converting Enzyme (FGE) Approach; 5.2.4 Split Inteins for Generating Site-Specifically Conjugated ADCs; 5.2.5 Glycan-Remodeling Approaches to Create Handles for Site-Specific Conjugation; 5.2.6 Other Enzymatic Approaches; 5.3 Conclusions; References; Chapter 6: Substance P-Saporin for the Treatment of Intractable Pain; 6.1 Introduction; 6.2 Animal and Human Tests of SP-SAP; 6.2.1 The Substance-P and Saporin Molecules.
• Publisher Details: Cham : Springer
• Publication Date: 2017
• Extent: 1 online resource
• Subjects: 615.7/98; Medicine; Antibody-toxin conjugates; Immunotoxins; MEDICAL -- Pharmacology; Antibody-toxin conjugates; Medical -- Immunology; Medical -- Oncology; Immunology; Pharmacology; Oncology; Toxicology; Monoclonal antibodies; Oncology; Oncology ; Electronic books
• Languages: English
• ISBNs: 9783319468778; 3319468774
• Related ISBNs: 9783319468754; 3319468758
• Notes: Note: Includes bibliographical references and index.; Note: Online resource; title from PDF title page (EBSCO, viewed April 13, 2017).
• Access Rights: Legal Deposit; Only available on premises controlled by the deposit library and to one user at any one time; The Legal Deposit Libraries (Non-Print Works) Regulations (UK).
• Access Usage: Restricted: Printing from this resource is governed by The Legal Deposit Libraries (Non-Print Works) Regulations (UK) and UK copyright law currently in force.